AI assistant
Apellis Pharmaceuticals, Inc. — Director's Dealing 2021
Feb 5, 2021
31417_dirs_2021-02-04_4f0e06bc-3896-4d2f-951c-595caad02ea9.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 5 — Annual Statement of Changes in Beneficial Ownership
Issuer: Apellis Pharmaceuticals, Inc. (APLS)
CIK: 0001492422
Period of Report: 2020-12-31
Reporting Person: Francois Cedric (Director, Chief Executive Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2020-12-29 | Common Stock | G | 300000 | $0.00 | Disposed | 813079 | Direct |
| 2020-12-29 | Common Stock | G | 300000 | $0.00 | Acquired | 300000 | Indirect |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 234411 | Indirect |
Footnotes
F1: The shares are held by the Francois Grossi Trust, for which Juliana Grossi, the spouse of the reporting person, serves as trustee. The reporting person disclaims beneficial ownership over the shares held by the Francois Grossi Trust except to the extent of his pecuniary interest therein.
F2: The securities are held by The Francois-DuBois Educational Trust, for which the Fiduciary Trust Company of New England serves as trustee. The reporting person disclaims beneficial ownership over the shares held by The Francois-DuBois Educational Trust except to the extent of his pecuniary interest therein.